Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Portfolio Pulse from
Xenetic Biosciences, Inc. has extended its collaboration with The Scripps Research Institute to advance its DNase-based oncology program. The program focuses on combining systemic DNase with CAR T-cell therapies for treating hematological cancers and metastatic melanoma.
November 07, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xenetic Biosciences has extended its collaboration with The Scripps Research Institute to further develop its DNase-based oncology program, which combines systemic DNase with CAR T-cell therapies. This extension could accelerate the program towards clinical proof-of-concept studies.
The extension of the collaboration with a reputable institute like The Scripps Research Institute is a positive development for Xenetic Biosciences. It indicates progress in their DNase-based oncology program, which could lead to clinical studies. This is likely to be viewed positively by investors, potentially boosting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100